Ante la incertidumbre de ciertos sectores de la sociedad respecto de si vacunar a los niños, niñas y adolescentes contra el SARS-CoV-2 es seguro o no, una discusión que fue cruzada por tensiones políticas, este martes la Sociedad Argentina de Pediatría (SAP) compartió un documento con una serie de argumentos para reafirmar que proteger a los más chicos ante el covid-19 es seguro y eficaz.
Thus, the organization has brought a vaccine for the youngest of the sea with Sinopharm, a vaccine approved for the organization between the ages of 3 and 11, or with Pfizer or Moderna, vaccines approved especially for other young people from 12 to 17 years old. in the face of the doubts of certain parents’ organizations promoted by the opposition.
As stated in the initial map of the SAP, “vaccination has proven to be effective” in young people and young people, which implies the intervention of the Chinese Sinopharm serum – which uses an inactivated virus platform – in the vaccination procedure for minors. . .
During their second separation, SAP recovered that, although the burden of the disease in young people is lower in adults, they can also infect and transmit the virus to other people.
Moreover, given the “multiple social interactions” of young people in a context where the adults guilty of such activities are well-vaccinated, younger people “appear to be the organization most likely to combat infection. “
“La protección activa con vacunas seguras y eficaces permitirá también, proteger a los niños ante la emergencia de nuevas variantes, Delta o Gamma entre otras, que se están propagando más fácilmente en la población pediátrica, que al momento no está completamente vacunada”, agrega también la SAP para alimentar la necesidad de vacunación pediátrica.
Finalmente, también asegura que la inoculación de los más chicos afianza “otros beneficios secundarios claramente relacionados”, tales como:
“All vaccines against Covid-19 used in our country involve inactivated viruses or viral genetic material, since the ability to cause immunity at the mucosal site does not occur with other attenuated viruses,” the SAP said in its press release. .
In fact, this generates a basic “epidemiological bar” that, due to society’s high vaccination policy, makes the transmission of SARS-CoV-2 difficult. To achieve this goal, but not to be an obstacle, it is best not to protect herd immunity to the maximum.
Covid vaccination in minors: young people over 3 to 11 years of age in the country are vaccinated
Regarding the vaccines that will be available in Argentina, the SAP has also established a series of issues that ensure the protection and effectiveness of the vaccines:
Además, el organismo especificó el proceso de vacunación en menores que se está llevando a cabo actualmente en el país y su evolución histórica: “En la República Argentina, en agosto de 2021 comenzó la vacunación de niñas, niños y adolescentes entre 12 a 17 años con comorbilidades, luego se continuó vacunando al mismo grupo etario sin comorbilidades con vacunas de RNA mensajero (Spikevax de Moderna y Comirnaty de Pfizer) y en octubre de 2021 se inició la vacunación en niñas y niños de 3 a 11 años con vacuna Sinopharm”, recuerda el comunicado de la SAP.
First, you should know that young people vaccinated with the first dose will have to get their complete rest in the corresponding period while “those who have not yet started the vaccination schedule are essential for us. “
Although the pediatric society highlighted that it precisely guarantees “monitoring of the protection and effectiveness of vaccines used in children, young people and adolescents,” it continues to advance vaccination in this age group, giving priority to young people and adolescents with chronic illnesses.